On May 12, 2022 GT Biopharma, Inc. (NASDAQ: GTBP), an immuno-oncology company focused on developing innovative therapeutics based on the Company’s proprietary tri-specific natural killer (NK) cell engager, TriKE protein biologic technology platform, reported that management will present at H.C. Wainwright’s Hybrid Global Investment Conference (Press release, GT Biopharma, MAY 12, 2022, https://ir.gtbiopharma.com/news/detail/252/gt-biopharma-to-participate-at-h-c-wainwright-hybrid-global-investment-conference [SID1234614389]). The conference will take place May 23-26, 2022 at the Fontainebleau, Miami Beach Hotel, Miami Beach, Florida.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

H.C. Wainwright Global Investment Conference – May 23-26, 2022

If you are interested in arranging a 1×1 meeting request with management, please contact your bank conference representative. To access the archived recording for replay, please see the Presentations section of GT Biopharma’s corporate website.